We are a research-based, biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of neurodegenerative diseases with high unmet medical need.
Our global patent estate, which includes 85 issued patents spanning composition of matter and methods of use of various compounds for the treatment of neurodegenerative diseases (e.g. tauopathies and proteinopathies), protects our proprietary interest in novel antioxidants, amyloid beta monoclonal antibodies, tau monoclonal antibodies and related platform technologies.
Our current focus is to establish proof of concept for our potent anti-oxidant, OX-1 (indole-3-propionic acid) a therapeutic compound, which prevents oxidative stress by a combination of hydroxyl radical scavenging activity and metal chelation. We licensed OX-1 from New York University and South Alabama Medical Science Foundation on an exclusive basis.